WO1995003056A1 - Hepatitis c virus proliferation inhibitor - Google Patents

Hepatitis c virus proliferation inhibitor Download PDF

Info

Publication number
WO1995003056A1
WO1995003056A1 PCT/JP1994/001187 JP9401187W WO9503056A1 WO 1995003056 A1 WO1995003056 A1 WO 1995003056A1 JP 9401187 W JP9401187 W JP 9401187W WO 9503056 A1 WO9503056 A1 WO 9503056A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus
acid
virus proliferation
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1994/001187
Other languages
English (en)
French (fr)
Inventor
Tsuneo Ozeki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tokyo Tanabe Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Tanabe Co Ltd filed Critical Tokyo Tanabe Co Ltd
Priority to CA002167537A priority Critical patent/CA2167537A1/en
Priority to EP94921121A priority patent/EP0773029A4/en
Priority to US08/586,633 priority patent/US5846964A/en
Priority to AU71958/94A priority patent/AU688344B2/en
Publication of WO1995003056A1 publication Critical patent/WO1995003056A1/ja
Priority to KR1019960700254A priority patent/KR960703604A/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Definitions

  • the present invention relates to a hepatitis C virus growth inhibitor comprising bile acid as an active ingredient.
  • Non-A, non-B hepatitis accounts for 95 to 100% of post-transfusion hepatitis and 40 to 50% of sporadic hepatitis.
  • HCV hepatitis C virus
  • Interferon is known as a drug that has an inhibitory effect on the growth of this hepatitis C virus, but its effective rate is as low as 30 to 40%, relapse of 60 to 70% after discontinuation of administration, fever, headache, Many problems have been pointed out, including the appearance of various side effects such as influenza-like symptoms such as vomiting and leukopenia at a high rate.
  • bile acids are drugs known as bile drugs, liver function improving agents and the like.
  • virus growth inhibitory effect of bile acids antiviral effects against herpes virus, human immunodeficiency virus, influenza virus, parainfluenza virus, etc. are known (Japanese Patent Application Laid-Open No. 59-167177).
  • bile acids Is still known to have hepatitis C virus growth inhibitory action Not in.
  • 62-77333 discloses a suppository formulation containing ursodexoxycholate and interferon, wherein the bile acid is absorbed by colorectal administration of intarfu mouth. It is only used as an enhancer and does not imply that bile acids have an inhibitory effect on hepatitis C virus growth.
  • An object of the present invention is to provide a novel hepatitis C virus growth inhibitor having high efficacy and no side effects. Disclosure of the invention
  • the present inventors have conducted intensive studies on hepatitis C and the virus, and as a result, have found that bile acid has an inhibitory effect on the growth of hepatitis c virus, and thus completed the present invention. That is, the present invention is a hepatitis c virus growth inhibitor comprising bile acid or a physiologically acceptable salt thereof as an active ingredient.
  • the bile acids used in the present invention include free bile acids such as ursodeoxycholic acid and chenodeoxycholic acid and conjugated bile acids such as tauroursodeoxycholic acid.
  • the physiologically acceptable salt include an alkali metal salt such as a sodium salt. These can be produced using well-known production methods for bile acids.
  • Examples of the administration form of the hepatitis C virus growth inhibitor of the present invention include oral administration by tablets, capsules, granules, powders, syrups and the like, and parenteral administration by injections or suppositories. These preparations can be produced by known methods using additives such as excipients, binders, disintegrants, lubricants, stabilizers, and flavoring agents.
  • the dosage varies depending on symptoms, age, etc., but usually 1 for adults, 800 to 300 mg orally, preferably 1200 to 1800 mg, more preferably 1400 to: I 600 mg parenterally. 30 ⁇ : I 200 mg, preferably 50 ⁇ : I 00 mg, Desirably 100 mg to 60 mg! It can be administered once or in several divided doses. For parenteral administration, it is preferable to use intravenous drip.
  • ursodeoxycholic acid ursodeoxycholic acid
  • tauroursodeoxycholic acid TUDCA
  • Liver biopsy was performed on sixty-six patients with chronic hepatitis C (S j, S 2 , S 3 , S 5 and S 6 ) aged 40 to 60 years old who were HCV antibody-positive and HC VRNA-positive. Histology was performed on the half by HE and Azan staining using formalin fixation, and the rest was ground in a mortar using sea sand to obtain the supernatant. Adding the supernatant to E ag 1 e one MEM medium culture C hang cells (1 0% FCS added), 3 7 ° C, 5 % C 0 2 9 3 0 minutes warmed in 5% air, Infected.
  • the cells were centrifuged at 180 rpm, and the precipitated cells were added with UDCA (25 and 50 ⁇ ⁇ in the culture solution), TUDC ⁇ (20 and 50 ⁇ in the culture solution) and was added to E ag 1 e one MEM medium without additives (FCS ⁇ beauty antibiotics added), lxl O 5 cell Zs and LIDE, on LAB one TEKC ha mb erslide 3 7 ° C , 5% C 0 9 9 5 Culture was performed in% air for 1 week at 110 cells and for 2 weeks in TUDCA.
  • HCV HCV RNA reverse transcription PCR method
  • core antibody Okayama monoclonal antibody
  • HCV was stained by immunostaining using, and the number of positive cells was counted with a light microscope to determine the infection rate of HCV to Chang cells.
  • ABC ABC method using HRS was used. HRS is an abbreviation for Horse R adishstaining, and ABC is an abbreviation for avidin-biotinco mp 1 ex.
  • infection was separately confirmed by the insituhybridization method.
  • Tables 1 and 2 show the results of the HCV growth inhibition test of UDCA and TUDCA, respectively.
  • the control in the table shows the results of the same test as above without adding the supernatant.
  • the UDCA-added group and the TUDCA-added group significantly suppressed HCV proliferation compared to the non-added group.
  • UDCA was performed using 9-week-old Wistar male and female rats and 8-week-old dd male and female mice, and TUDCA was performed using 8- to 11-month-old male and female Beagle dogs and 6-week-old SD male and female rats.
  • a toxicity test (LD5 () ) was performed. Tables 4 and 5 show the results. Table 4.
  • Acute toxicity test results of UDCA [LD 50 value (mg g kg)]
  • bile acids significantly suppress the growth of hepatitis C virus and are extremely safe, and are useful as hepatitis C virus growth inhibitors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

明 細 書
C型肝炎ウィルス増殖抑制剤 技術分野
本発明は、 胆汁酸を有効成分とする C型肝炎ウィルス増殖抑制剤に関 する。 背景技術
非 A非 B型肝炎は、 輸血後肝炎の 9 5〜 1 0 0 %、 散発性肝炎の 4 0 〜50 %を占め、 慢性化しやすく、 慢性肝炎、 肝硬変を経て肝癌へ移行 する率が高い。 そして、 近年 C型肝炎ウィルス （HCV) が同定され、 従来非 A非 B型肝炎と呼ばれていたものほとんどが C型肝炎ウィルスに よるものであることが明らかになつてきた。
この C型肝炎ウィルスの増殖抑制作用を有する薬剤としてィンターフ ェロンが知られているが、 有効率が 30〜40 %と低いこと、 投与中止 後 60〜7 0 %が再燃すること、 発熱、 頭痛、 嘔吐等のィンフルェンザ 様症状や白血球減少等多様な副作用が高率に出現すること等多くの問題 が指摘されている。
—方、 胆汁酸は、 利胆剤、 肝機能改善剤等として公知の薬剤である。 胆汁酸のウィルス増殖抑制作用については、 ヘルぺスウィルス、 ヒ ト免 疫不全ウィルス、 インフルエンザウイルス、 パラインフルエンザウィル ス等に対する抗ウィルス作用が知られているが （特開昭 59 - 1 675 1 7 号公報、 特開昭 6 3— 3 0 1 823号公報、 特開平 2— 1 6 7 235号 公報、 特表平 4— 5005 1 4号公報、 特表平 4一 500670号公報） 、 胆汁酸が C型肝炎ウィルスの増殖抑制作用を有することは未だ知られて いない。 また、 特開昭 62 - 77333号公報には、 ウルソデォキシコ一 ル酸塩とィンターフ 口ンを含有する坐薬製剤が開示されているが、 こ こでの胆汁酸はィンターフユ口ンの結腸直腸投与における吸収促進剤と して使用されているに過ぎず、 胆汁酸が C型肝炎ウィルスの増殖抑制作 用を有することを何ら示唆するものではない。
本発明の目的は、 有効性が高く副作用のない新規な C型肝炎ウィルス 増殖抑制剤を提供することにある。 発明の開示
本発明者は、 C型肝炎及び該ウィルスについて鋭意研究を続けた結果、 胆汁酸が c型肝炎ウィルスの増殖抑制作用を有することを見出し、 本発 明を完成した。 即ち、 本発明は、 胆汁酸又はその生理的に許容される塩 を有効成分とする c型肝炎ウィルス増殖抑制剤である。
本発明で使用される胆汁酸としては、 ウルソデォキシコール酸、 ケノ デォキシコール酸等の遊離型胆汁酸又はタウロウルソデォキシコール酸 等の抱合型胆汁酸が挙げられる。 また、 生理的に許容される塩とは、 例 えばナトリウム塩等のアルカリ金属塩等が挙げられる。 これらは、 胆汁 酸に関する周知の製造法を利用して製造することができる。
本発明の C型肝炎ウィルス増殖抑制剤の投与形態としては、 錠剤、 力 プセル剤、 顆粒剤、 散剤若しくはシロップ剤等による経口投与又は注射 剤若しくは坐剤等による非経口投与が挙げられる。 これらの製剤は、 賦 形剤、 結合剤、 崩壊剤、 滑沢剤、 安定剤、 矯味矯臭剤等の添加剤を用い て、 周知の方法で製造することができる。 その使用量は症状、 年齢等に より異なるが、 通常成人に対して 1 曰、 経口で 80 0〜3 0 0 0mg、 望ましくは 1200〜1800mg、 更に望ましくは 1400〜： I 600mg を、 非経口で 3 0〜： I 20 0mg、 望ましくは 50〜： I 0 0 0mg、 更 に望ましくは 1 0 0〜6 0 O m gを、 ！ 曰 1回又は数回に分けて投与す ることができる。 なお、 非経口では、 点滴静脈内投与法を用いるのが望 ましい。 発明を実施するための最良の形態
胆汁酸の C型肝炎ウィルス増殖抑制試験、 臨床試験及び急性毒性試験 の結果を以下に詳述する。 胆汁酸としては、 ウルソデォキシコール酸 (UD C A) 及びタウロウルソデォキシコール酸 （T U D C A) を代表 化合物として使用した。
(C型肝炎ウィルス増殖抑制試験）
4 0 - 6 0才の H C V抗体陽性、 H C VRN A陽性の C型慢性肝炎患 者 6名 （S j 、 S 2、 S3、 、 S5 及び S 6 ) の肝生検を施行し、 その半分をフオルマリン固定による H E及び A z a n染色で組織診断を 行い、 残部は海砂を用い乳鉢上で磨砕し、 その上清液を得た。 その上清 液を培養 C h a n g細胞の E a g 1 e一 MEM培地 （1 0 % F C S添加） に添加、 3 7°C、 5 % C 02 9 5 % a i r中で 3 0分加温し、 感染さ せた。 ついで、 1 8 0 0 r p mで遠心し、 沈殿細胞をそれぞれ UD C A 添加 （培養液中濃度 2 5及び 5 0 βΜ) 、 T UD C Α添加 （培養液中濃 度 2 0及び 5 0 βΜ) 及び無添加の E a g 1 e一 MEM培地 （F C S及 び抗生物質添加） に添加し、 l x l O5 c e l l Zs l i d eとし、 LAB 一 T E K C h a mb e r s l i d e上で 3 7 °C、 5 % C 09 9 5 % a i r中で、 110じ では 1週間、 T U D C Aでは 2週間培養した。 これらの培養 C h a n g細胞中の H C Vの存在は、 H C V RN A逆転 写 P C R法 （L a n c e t 3 3 5巻 1 4 1 9 — 2 2頁 1 9 9 0年に記載 の方法に準じた。 ） を用い 1 7 8 b p (ベースペア） バンドの出現によ り確実に確認された。 また、 c o r e抗体 （岡山のモノクロナール抗体） を用いた免疫染色により H C Vを染色し、 陽性細胞を光学顕微鏡で計数 することにより、 H C Vの C h a n g細胞への感染率を求めた。 免疫染 色は HRSを用いた AB C法を用いた。 HRSは、 H o r s e R a d i s h s t a i n i n gの略語であり、 また、 A B Cは、 a v i d i n — b i o t i n c o mp 1 e xの略語を意味する。 なお、 i n s i t u h y b r i d i z a t i o n法でも別途に感染を確認した。
UD C A及び T UD C Aの H C V増殖抑制試験の結果をそれぞれ表 1 及び表 2に示す。 なお、 表中のコントロールは、 上清液を添加せずに上 記と同様に試験した結果を示す。
O C
O
表 1 . U D C Aの H C V増殖抑制試験結果 （感染率 ： ％)
Ο 0
U D t A 濃 度
0 βΜ 2 5 μΜ 5 0 Μ コン トローノレ 29.7土 5.5 21.4± 0.9
Figure imgf000006_0001
45.2土 4.2 16- 6土 2.0 患 " 2 50. 1土 7.4 23.9土 7.0 17.2士 3.3 患 " 3 38.9土 8.2
Figure imgf000006_0002
18· 5土 2.8
表 2. T U D C Aの H C V増殖抑制試験結果 （感染率 ： ％)
Figure imgf000007_0001
表 1及び表 2から明らかなように、 U D C A添加群及び T U D C A添 加群は無添加群に比べ、 有意に HCVの増殖を抑制した。
(臨床試験）
52 - 72才の C型慢性肝炎患者 8名 （S7、 S8、 S9、 S 1Q、 Sn 、 S12、 S13及び S14 ) に、 UDCAを 1日当り 1200— 1500mg で 0. 5— 6ヶ月間経口投与した。 それぞれの患者の UD C A投与前後 の血清中 H C VRN A定量値を表 3に示した。
表 3 . U D C A投与前後の血清中 H C V R N A定量値
Figure imgf000008_0001
表 3から明らかなように、 C型慢性肝炎患者の H C Vの増殖は U D C A の投与により顕著に抑制された。
(急性毒性試験）
UD C Aは 9週齢のウイスター系雌雄ラッ ト及び 8週齢の d d系雌雄 マウスを用い、 TUDCAは 8〜1 1ヶ月齢の雌雄ビーグル犬及び 6週 齢の SD系雌雄ラッ トを用いて急性毒性試験 （LD5()) を行った。 それ ぞれの結果を表 4及び表 5に示す。 表 4. U D C Aの急性毒性試験結果 [L D50値 （m gZ k g) ]
Figure imgf000009_0001
表 3及び表 4から明らかなように、 U D C A及び T U D C Aの急性毒 性は極めて低く、 安全性の高い薬剤である。 産業上の利用可能性
このように、 胆汁酸は C型肝炎ウィルスの増殖を顕著に抑制するうえ、 極めて安全性が高く、 C型肝炎ウィルス増殖抑制剤として有用である。

Claims

請 求 の 範 囲
1 . 胆汁酸又はその生理的に許容される塩を有効成分とする C型肝炎ゥ ィルス増殖抑制剤。
2 . 胆汁酸がウルソデォキシコール酸又はタウロウルソデォキシコール 酸である請求項 1記載の C型肝炎ウィルス増殖抑制剤。
PCT/JP1994/001187 1993-07-19 1994-07-19 Hepatitis c virus proliferation inhibitor Ceased WO1995003056A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002167537A CA2167537A1 (en) 1993-07-19 1994-07-19 Hepatitis c virus proliferation inhibitor
EP94921121A EP0773029A4 (en) 1993-07-19 1994-07-19 HEPATITIS C VIRUS PROLIFERATION INHIBITOR
US08/586,633 US5846964A (en) 1993-07-19 1994-07-19 Hepatitis C virus proliferation inhibitor
AU71958/94A AU688344B2 (en) 1993-07-19 1994-07-19 Hepatitis C virus proliferation inhibitor
KR1019960700254A KR960703604A (ko) 1993-07-19 1996-01-18 C형 간염 바이러스 증식 억제제(Hepatitis C Virus Proliferation Inhibitor)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5/178072 1993-07-19
JP17807293 1993-07-19
JP28839193 1993-11-17
JP5/288391 1993-11-17

Publications (1)

Publication Number Publication Date
WO1995003056A1 true WO1995003056A1 (en) 1995-02-02

Family

ID=26498376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1994/001187 Ceased WO1995003056A1 (en) 1993-07-19 1994-07-19 Hepatitis c virus proliferation inhibitor

Country Status (6)

Country Link
US (1) US5846964A (ja)
EP (1) EP0773029A4 (ja)
KR (1) KR960703604A (ja)
AU (1) AU688344B2 (ja)
CA (1) CA2167537A1 (ja)
WO (1) WO1995003056A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
JP2011500558A (ja) * 2007-10-10 2011-01-06 ハンオル バイオファーマ カンパニー，リミテッド ＨＭＧ−ＣｏＡ還元酵素抑制剤と胆汁酸を含むＣ型肝炎治療用薬学組成物
JP2021046366A (ja) * 2019-09-18 2021-03-25 救心製薬株式会社 センソ及びゴオウの医薬用途

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
AU3216695A (en) * 1994-08-29 1996-03-22 University Of North Carolina At Chapel Hill, The Lipid analogs for treating viral infections
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
CN100558407C (zh) * 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
JP2005502580A (ja) * 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
KR20030041130A (ko) * 2001-05-29 2003-05-23 코닌클리케 필립스 일렉트로닉스 엔.브이. 금속-세라믹 접착
MXPA04001917A (es) * 2001-08-31 2004-06-15 Thomson Licensing Sa Contador de secuencia para una corriente audio-visual.
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1480982A4 (en) * 2002-02-14 2007-08-01 Pharmasset Inc MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
AU2003215826A1 (en) * 2002-04-01 2003-10-13 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
EP1545545A4 (en) * 2002-08-01 2008-09-03 Pharmasset Inc COMPOUNDS WITH THE BICYCLO 4.2.1 NONAN SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE / I INFECTIONS
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20040214178A1 (en) * 2003-04-24 2004-10-28 Agouron Pharmaceuticals, Inc. Reporter-selectable Hepatitis C virus replicon
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2361845T3 (es) * 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
RU2294207C2 (ru) * 2005-04-18 2007-02-27 Учебно-научный центр Медицинского центра Управления делами Президента РФ Способ лечения заболеваний, обусловленных и сопровождающихся нарушением метаболизма желчных кислот и холестерина
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
AU2007230989A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
EP2518079A3 (en) 2006-04-11 2012-12-12 Novartis AG HCV/HIV inhibitors and their uses
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008106166A2 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
CN103179966B (zh) 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
MD4177C1 (ro) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
BR112014002365A2 (pt) 2011-08-03 2017-02-21 Cytheris interleucina-7 (il-7)
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
MD596Z (ro) * 2012-10-09 2013-09-30 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de tratament al hepatitei virale cronice C la copii
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277333A (ja) * 1985-09-30 1987-04-09 Toray Ind Inc インタ−フエロン坐薬製剤
JPS63301823A (ja) * 1987-03-17 1988-12-08 パブリック・ヘルス・ラボラトリー・サーヴィス・ボード ウイルス感染の治療及び予防用組成物
JPH02142731A (ja) * 1988-11-25 1990-05-31 Kenji Katagiri 胆汁うっ滞改善剤
WO1992018524A1 (en) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. N-alkyl-tauroursodeoxycholic acids and their therapeutically active derivatives, a process for their preparation and pharmaceutical compositions containing them
JPH04349885A (ja) * 1991-05-29 1992-12-04 Teijin Ltd Ｃ型肝炎ウイルスのエンビロープ領域核酸断片およびその検出方法
JPH05142231A (ja) * 1991-10-08 1993-06-08 Kokuritsu Yobou Eisei Kenkyusho Ｃ型肝炎診断薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2272883A (en) * 1982-12-22 1984-06-28 Herpes Pharmaceutical Inc. Pharmaceutical compositions of steriods for treatment of herpes simplex infections
NO178843C (no) * 1988-07-11 1996-06-19 Sspl Sa Safe Sex Prod Licens Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer
KR900701278A (ko) * 1988-09-20 1990-12-01 시. 비. 크래이그 바이러스 감염 치료용 담즙산
JPH04500514A (ja) * 1989-09-01 1992-01-30 デイアマルト　アクチエンゲゼルシヤフト ５β―コラン―２４―酸―誘導体の２―ヒドロキシ―Ｎ，Ｎ，Ｎ―トリメチル―エタナミニウム塩
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277333A (ja) * 1985-09-30 1987-04-09 Toray Ind Inc インタ−フエロン坐薬製剤
JPS63301823A (ja) * 1987-03-17 1988-12-08 パブリック・ヘルス・ラボラトリー・サーヴィス・ボード ウイルス感染の治療及び予防用組成物
JPH02142731A (ja) * 1988-11-25 1990-05-31 Kenji Katagiri 胆汁うっ滞改善剤
WO1992018524A1 (en) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. N-alkyl-tauroursodeoxycholic acids and their therapeutically active derivatives, a process for their preparation and pharmaceutical compositions containing them
JPH04349885A (ja) * 1991-05-29 1992-12-04 Teijin Ltd Ｃ型肝炎ウイルスのエンビロープ領域核酸断片およびその検出方法
JPH05142231A (ja) * 1991-10-08 1993-06-08 Kokuritsu Yobou Eisei Kenkyusho Ｃ型肝炎診断薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL RES., Vol. 24, No. 2-3, 1994, MUTCHNICK MILTON G. et al., "Prospectives on the Treatment of Chronic Hepatitis B and Chronic Hepatitis C With Thymic Peptides and Antiviral Agents", pages 245-257. *
See also references of EP0773029A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7727976B2 (en) 2001-08-29 2010-06-01 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
JP2011500558A (ja) * 2007-10-10 2011-01-06 ハンオル バイオファーマ カンパニー，リミテッド ＨＭＧ−ＣｏＡ還元酵素抑制剤と胆汁酸を含むＣ型肝炎治療用薬学組成物
JP2021046366A (ja) * 2019-09-18 2021-03-25 救心製薬株式会社 センソ及びゴオウの医薬用途

Also Published As

Publication number Publication date
KR960703604A (ko) 1996-08-31
EP0773029A4 (en) 1997-09-03
EP0773029A1 (en) 1997-05-14
AU7195894A (en) 1995-02-20
AU688344B2 (en) 1998-03-12
CA2167537A1 (en) 1995-02-02
US5846964A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
US5846964A (en) Hepatitis C virus proliferation inhibitor
JP5539363B2 (ja) インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
Dunnick et al. Clinical trials with exogenous interferon: summary of a meeting
US6660721B2 (en) Anti-HCV nucleoside derivatives
US5422344A (en) Method of treating retroviral infections in mammals
MX2012004971A (es) Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
JP2001072585A (ja) ウイルス性心筋炎の予防または治療薬剤
WO2020259706A1 (zh) 氨来占诺用于制备抗肝炎病毒药物的用途
CN102844028B (zh) Hcv大环抑制剂、非核苷和核苷的组合
JPH04234320A (ja) 抗ｈｂｖ剤
US9084758B2 (en) Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof
CN115884770B (zh) 治疗冠状病毒感染的联用药物及治疗方法
JP2021523129A5 (ja)
JP5061352B2 (ja) 肝臓疾患治療剤及び肝機能改善剤
JPWO1995003056A1 (ja) Ｃ型肝炎ウイルス増殖抑制剤
JPWO2009154248A1 (ja) Ｈｂｖ感染症を治療または予防するための医薬組成物
CN106581052B (zh) 柠檬酸根离子和铁离子在抑制rna病毒中的应用
JPH05262653A (ja) 先天性免疫不全症候群（エイズ）治療用組成物
CN111228491B (zh) Ip-10抑制剂在预防和/或治疗寨卡病毒感染中的应用
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
JP5500751B2 (ja) 肝移植後の再感染防御剤
JPH06206822A (ja) Ｂ型肝炎ウイルス抑制剤
JPH11193242A (ja) 抗インフルエンザウイルス剤
WO2005004817A2 (en) Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases
CN111265530A (zh) 一种治疗hbv感染的联合用药物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2167537

Country of ref document: CA

Ref document number: 08586633

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1994921121

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994921121

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1994921121

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994921121

Country of ref document: EP